Skip To Main Content
Chi KN on Muck Rack

Chi KN

As seen in: Sparda-Bank web.Börsenforum
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Chi KN’s profile

Articles by Chi KN

PSD Bank Rhein-Ruhr eG

|
By De J, Chi KN, Epstein AJ, Ivanova JI. Real-world
| Sparda-Bank web.Börsenforum
* Pluvicto(TM) plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC)(1 ) * Most patients with mHSPC progress to metastatic castration-resistant prostate cancer, underscoring urgent need for new therapies that can reduce risk of progression in earlier disease settings(2)(,3 ) * The safety profile and tolerability of Pluvicto in...
Open in Who Shared View Duplicates (37) Issue with article?

PSD Bank Rhein-Ruhr eG

|
By de Wit R, De J, Chi KN, Berry WR
| Sparda-Bank web.Börsenforum
* Phase III PSMAfore trial with Pluvicto(TM) met its primary endpoint of radiographic progression-free survival (rPFS) with a HR of 0.41(1); Pluvicto more than doubled median rPFS to 12.0 months per updated analysis*(1) * Pluvicto also showed improved quality of life compared to daily oral ARPI, along with improvements in other clinically meaningful efficacy endpoints(1) * Overall survival (OS) data interpretation at second interim analysis was confounded by 84% crossover(1); PSMAfore...
Open in Who Shared View Duplicates (239) Issue with article?

Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects - PubMed

|
By Byron M. Espina, Smith MR, George DJ, Chi KN
| ncbi.nlm.nih.gov
doi: 10.18553/jmcp.2023.29.7.758. Affiliations Affiliations 1 Hematology-Oncology Division, Massachusetts General Hospital, Harvard Medical School, Boston. 2 Medical Oncology, Peter MacCallum Cancer Centre and the University of Melbourne, Australia. 3 Medical Oncology, Duke University School of Medicine, Duke Cancer Institute, Durham, NC. 4 Division of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, Canada.
Open in Who Shared Issue with article?

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial - PubMed

|
By Chi KN, Smith MR, Small EJ, Rathkopf DE
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (623) Issue with article?

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

|
By Tomasz Byrski, Smith MR, Seoksoo Byun, Chi KN
| nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (412) Issue with article?
Show More